Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
07 mars 2023 08h30 HE
|
Dyadic International, Inc.
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 ...
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
28 févr. 2023 08h00 HE
|
BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
Tamiflu (Oseltamivir Phosphate) Market to Surpass US$ 978.6 Million by 2030, Says Coherent Market Insights (CMI)
20 févr. 2023 10h00 HE
|
CMI
Burlingame, Feb. 20, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global Tamiflu (oseltamivir phosphate) market is estimated to be valued at US$ 889.2 million in 2022 and is...
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
16 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
08 févr. 2023 16h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development
06 févr. 2023 10h15 HE
|
Blue Water Vaccines Inc.
CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial...
Influenza Diagnostics Market will worth USD 2.58 billion by 2030 : GreyViews
27 janv. 2023 13h00 HE
|
GreyViews
Pune India, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
24 janv. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
21 déc. 2022 08h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
14 déc. 2022 08h30 HE
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...